Genmab A/S

March 14, 2026 • Author: Phil Ratcliff

Item	Proposal	Vote
2	Presentation and adoption of the audited Annual Report and discharge of Board of Directors and Executive Management	✓ For(849.539)
3	Resolution on the distribution of profits as recorded in the adopted Annual Report	✓ For(849.539)
4	Advisory vote on the Compensation Report	✓ For(849.539)
5	Election of members of the Board of Directors:
5a	Re-election of Deirdre P. Connelly	✓ For(849.539)
5b	Re-election of Pernille Erenbjerg	✓ For(849.539)
5c	Re-election of Rolf Hoffmann	✓ For(849.539)
5d	Re-election of Elizabeth O’Farrell	✓ For(849.539)
5e	Re-election of Dr. Paolo Paoletti	✓ For(849.539)
5f	Re-election of Dr. Anders Gersel Pedersen	Abstain(849.539)
6	Election of auditor: Re-election of Deloitte Statsautoriseret Revisionspartnerselskab	✓ For(849.539)
7	Proposals from the Board of Directors:
7a	Approval of remuneration to the Board of Directors for 2026	✓ For(849.539)
7b	Proposal to reduce the Company’s share capital for the purpose of cancelling treasury shares	✓ For(849.539)
8	Authorization of the Chair of the General Meeting to register resolutions passed by the General Meeting	✓ For(849.539)

Attachments

📄

Genmab_General_Meeting_Information.pdf 0.3 MB

📄

Genmab_2025_Annual_Report.pdf 12.2 MB

This article was written for information purposes only and its content should not be construed by any consumer and/or prospective client as rebel Financial's solicitation to affect, or attempt to affect transactions in securities, or the rendering of personalized investment advice for compensation. No client or prospective client should assume that any such discussion serves as the receipt of, or a substitute for, personalized advice from rebel Financial, or from any other investment professional. See our disclosures page for more information.